Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344284 | 0.73 | TSHR (0.37) | ALDH1A1 | |
| SCHEMBL609663 | 0.67 | — | — | |
| SCHEMBL188597 | 0.67 | — | — | |
| SCHEMBL10933886 | 0.67 | LMNA (0.33) | ALDH1A1 | |
| SCHEMBL7960409 | 0.64 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7423100 | 0.64 | LMNA (0.37) | ALDH1A1 | |
| SCHEMBL19641937 | 0.62 | ALOX5 (0.39) | — | |
| SCHEMBL22616909 | 0.62 | LMNA (0.37) | ALDH1A1 | |
| SCHEMBL2465797 | 0.61 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL17791665 | 0.60 | LMNA (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4777515-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-7498332-B2 | Therapy for cerebral vasospasm | DUKE UNIVERSITY (US) | 2009-03-03 | — | — | US | claimed |
| EP-1124950-B1 | Morpholino based p53 antisense oligonucleotide, and uses thereof | AVI BIOPHARMA INC (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005049811-A1 | RADIOMINETIC METHOD OF PRODUCING A RODENT XENOGRAFT MODEL HAVING HUMANIZED MAMMARY FAT PAD | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2005-06-02 | — | — | WO | claimed |
| US-20020160001-A1 | Therapy for cerebral vasospasm | DUKE UNIVERSITY | 2002-10-31 | — | — | US | claimed |
| JP-2002528464-A | — | — | 2002-09-03 | — | — | JP | claimed |
| US-6365577-B1 | p53 antisense agent and method | AVI BIOPHARMA, INC. | 2002-04-02 | — | — | US | claimed |
| EP-1124950-A2 | p53 ANTISENSE AGENT AND METHOD | Avi Biopharma, Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| WO-2000024885-A2 | p53 MORPHOLINO-BASED ANTISENSE | AVI BIOPHARMA, INC. (US) | 2000-05-04 | — | — | WO | claimed |
| US-7498332-B2 | Therapy for cerebral vasospasm | DUKE UNIVERSITY (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1667727-B1 | POLYAMINE-METAL CHELATOR CONJUGATES | UNIV FLORIDA (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20060211773-A1 | Polyamine-metal chelator conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1124950-B1 | Morpholino based p53 antisense oligonucleotide, and uses thereof | AVI BIOPHARMA INC (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1667727-A2 | POLYAMINE-METAL CHELATOR CONJUGATES | University of Florida Research Foundation, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6365577-B1 | p53 antisense agent and method | AVI BIOPHARMA, INC. | 2002-04-02 | — | — | US | disclosed |
| EP-1124950-A2 | p53 ANTISENSE AGENT AND METHOD | Avi Biopharma, Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024885-A2 | p53 MORPHOLINO-BASED ANTISENSE | AVI BIOPHARMA, INC. (US) | 2000-05-04 | — | — | WO | disclosed |
| US-5736129-A | Flow cytometric pharmacosensitivity assay and method of cancer treatment | SHAKER CORPORATION, A DELAWARE CORPORATION | 1998-04-07 | — | — | US | disclosed |
| WO-1997019189-A1 | FLOW CYTOMETRIC PHARMACOSENSITIVITY ASSAY AND METHOD OF CANCER TREATMENT | MEDENICA RAJKO D (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0331505-A1 | A method for purification of liposome composition | Takeda Chemical Industries, Ltd. (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211773-A1 | Polyamine-metal chelator conjugates | SLC40A1, SLC7A1, CATSPER1 | ALDH1A1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.